Prostacyclin (PGI2) is released by vascular endothelial cells and serves as a potent vasodilator, inhibitor of platelet aggregation, and moderator of vascular smooth muscle cell proliferation-migration-differentiation (Narumiya et al. 1999). The function of protacyclin is mediated via a seven transmembrane GPCR, IP1, which is known to couple to Gs and Gq signaling pathways. Mice lacking the IP1 receptor have shown increased susceptibility to thrombosis (Murata et al. 1997), enhanced injury-induced vascular proliferation and platelet activation (Cheng et al. 2002), as well as reperfusion injury (Xiao et al. 2001). The recent world-wide withdrawal of selective COX-2 inhibitors, rofecoxib (Vioxx™) and valdecoxib (Bextra™), is also due to their discriminating suppression of COX-2-derived prostacyclin and IP1-mediated cardioprotective effects, leading to increased risk of cardiovascular events (Fitzgerald 2004). Millipore's cloned human IP1-expressing cell line is made in the Chem-1 host, which supports high levels of recombinant IP1 expression on the cell surface and contains high levels of the promiscuous G protein to couple the receptor to the calcium signaling pathway. Thus, the cell line is an ideal tool for screening for antagonists of interactions between IP1 and its ligands.